Symptoms

Aromatase inhibitor induced arthralgias

Dawn L. Hershman, Charles Lawrence Loprinzi, Bryan P. Schneider

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Recent clinical trials have demonstrated that aromatase inhibitors (AIs) are slightly more effective than tamoxifen at reducing breast cancer recurrences. However, breast cancer patients receiving AIs have a higher incidence of musculo-skeletal symptoms, particularly joint pain and stiffness. Musculoskeletal pain and stiffness can lead to noncompliance and increased utilization of health care resources. There is a suggestion that the syndrome is the result of estrogen deprivation and may share components with autoimmune diseases such as Sjögren’s syndrome. Several factors may increase the likelihood of developing AI arthralgia, such as prior chemotherapy, prior hormone replacement therapy, and increased weight; there are inconsistencies with regard to the data on genetic predispositions to this syndrome. While several studies have been done to evaluate interventions to treat or prevent AI arthral-gia, no clear treatment has emerged as being particularly benefi cial. Much of the research has been limited by small sample size, diffi culty blinding patients to placebo, inconsistent defi nitions of the syndrome, multiple patient reported outcomes, lack of objective outcome measures and heterogeneous patient populations. We are at the early stages of rese will ultimately improve the lives of women with breast cancer.

Original languageEnglish (US)
Pages (from-to)89-100
Number of pages12
JournalAdvances in Experimental Medicine and Biology
Volume862
DOIs
StatePublished - 2015

Fingerprint

Aromatase Inhibitors
Arthralgia
Breast Neoplasms
Stiffness
Musculoskeletal Pain
Chemotherapy
Health Resources
Hormone Replacement Therapy
Tamoxifen
Genetic Predisposition to Disease
Health care
Sample Size
Autoimmune Diseases
Estrogens
Joints
Placebos
Outcome Assessment (Health Care)
Clinical Trials
Hormones
Weights and Measures

Keywords

  • Aromatase inhibitors
  • Arthralgias
  • Breast cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Symptoms : Aromatase inhibitor induced arthralgias. / Hershman, Dawn L.; Loprinzi, Charles Lawrence; Schneider, Bryan P.

In: Advances in Experimental Medicine and Biology, Vol. 862, 2015, p. 89-100.

Research output: Contribution to journalArticle

@article{ed06cc5aa9584ba9a3e82e9a49657e9a,
title = "Symptoms: Aromatase inhibitor induced arthralgias",
abstract = "Recent clinical trials have demonstrated that aromatase inhibitors (AIs) are slightly more effective than tamoxifen at reducing breast cancer recurrences. However, breast cancer patients receiving AIs have a higher incidence of musculo-skeletal symptoms, particularly joint pain and stiffness. Musculoskeletal pain and stiffness can lead to noncompliance and increased utilization of health care resources. There is a suggestion that the syndrome is the result of estrogen deprivation and may share components with autoimmune diseases such as Sj{\"o}gren’s syndrome. Several factors may increase the likelihood of developing AI arthralgia, such as prior chemotherapy, prior hormone replacement therapy, and increased weight; there are inconsistencies with regard to the data on genetic predispositions to this syndrome. While several studies have been done to evaluate interventions to treat or prevent AI arthral-gia, no clear treatment has emerged as being particularly benefi cial. Much of the research has been limited by small sample size, diffi culty blinding patients to placebo, inconsistent defi nitions of the syndrome, multiple patient reported outcomes, lack of objective outcome measures and heterogeneous patient populations. We are at the early stages of rese will ultimately improve the lives of women with breast cancer.",
keywords = "Aromatase inhibitors, Arthralgias, Breast cancer",
author = "Hershman, {Dawn L.} and Loprinzi, {Charles Lawrence} and Schneider, {Bryan P.}",
year = "2015",
doi = "10.1007/978-3-319-16366-6_7",
language = "English (US)",
volume = "862",
pages = "89--100",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Symptoms

T2 - Aromatase inhibitor induced arthralgias

AU - Hershman, Dawn L.

AU - Loprinzi, Charles Lawrence

AU - Schneider, Bryan P.

PY - 2015

Y1 - 2015

N2 - Recent clinical trials have demonstrated that aromatase inhibitors (AIs) are slightly more effective than tamoxifen at reducing breast cancer recurrences. However, breast cancer patients receiving AIs have a higher incidence of musculo-skeletal symptoms, particularly joint pain and stiffness. Musculoskeletal pain and stiffness can lead to noncompliance and increased utilization of health care resources. There is a suggestion that the syndrome is the result of estrogen deprivation and may share components with autoimmune diseases such as Sjögren’s syndrome. Several factors may increase the likelihood of developing AI arthralgia, such as prior chemotherapy, prior hormone replacement therapy, and increased weight; there are inconsistencies with regard to the data on genetic predispositions to this syndrome. While several studies have been done to evaluate interventions to treat or prevent AI arthral-gia, no clear treatment has emerged as being particularly benefi cial. Much of the research has been limited by small sample size, diffi culty blinding patients to placebo, inconsistent defi nitions of the syndrome, multiple patient reported outcomes, lack of objective outcome measures and heterogeneous patient populations. We are at the early stages of rese will ultimately improve the lives of women with breast cancer.

AB - Recent clinical trials have demonstrated that aromatase inhibitors (AIs) are slightly more effective than tamoxifen at reducing breast cancer recurrences. However, breast cancer patients receiving AIs have a higher incidence of musculo-skeletal symptoms, particularly joint pain and stiffness. Musculoskeletal pain and stiffness can lead to noncompliance and increased utilization of health care resources. There is a suggestion that the syndrome is the result of estrogen deprivation and may share components with autoimmune diseases such as Sjögren’s syndrome. Several factors may increase the likelihood of developing AI arthralgia, such as prior chemotherapy, prior hormone replacement therapy, and increased weight; there are inconsistencies with regard to the data on genetic predispositions to this syndrome. While several studies have been done to evaluate interventions to treat or prevent AI arthral-gia, no clear treatment has emerged as being particularly benefi cial. Much of the research has been limited by small sample size, diffi culty blinding patients to placebo, inconsistent defi nitions of the syndrome, multiple patient reported outcomes, lack of objective outcome measures and heterogeneous patient populations. We are at the early stages of rese will ultimately improve the lives of women with breast cancer.

KW - Aromatase inhibitors

KW - Arthralgias

KW - Breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84931266021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931266021&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-16366-6_7

DO - 10.1007/978-3-319-16366-6_7

M3 - Article

VL - 862

SP - 89

EP - 100

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -